Universe Pharmaceuticals INC SEC filings document the disclosures of a Cayman Islands foreign private issuer operating a pharmaceutical production and distribution business in China. Form 6-K reports cover interim financial results, revenue and cost categories for company and third-party products, and current reports tied to governance and capital-structure matters.
The filing record also includes proxy materials and annual general meeting results, an equity incentive plan, and amendments related to ordinary-share structure, including Class A and Class B ordinary shares and authorized share capital. These filings describe shareholder voting matters, board and compensation arrangements, share-based awards and formal corporate actions affecting UPC securities.
Universe Pharmaceuticals INC reported that its 2025 annual general meeting of shareholders, originally convened on August 26, 2025, could not proceed because there were not enough shares represented to meet the required quorum. As a result, the meeting was formally adjourned to September 2, 2025 at 10:00 a.m. Beijing time.
The rescheduled meeting will take place at the company’s principal office at 265 Jingjiu Avenue in the Jinggangshan Economic and Technological Development Zone in Ji’an City, Jiangxi, China. The notice confirms that the company’s chief executive officer, Gang Lai, authorized this report.